

May 9, 2019

Completion of the enrollment of the final Cohort in Clinical Trial of RBM-007 for Treatment of Exudative Age-related Macular Degeneration

We are pleased to announce that all patients of Cohort 3 have been enrolled and treated with RBM-007 in the phase I/IIa trial for the treatment of exudative age-related macular degeneration (AMD) in the United States. No serious adverse events have occurred so far in the entire trial. Clinical data is being analyzed and scheduled to become available in June 2019.

This PI/IIa trial is an open label, non-controlled, dose-escalating study assessing mainly the safety and tolerability of a single intravitreal injection of RBM-007 in nine subjects.

See ClinicalTrials.gov for more information:

<https://clinicaltrials.gov/ct2/show/NCT03633084>

See also our company's website about this trial:

<https://www.ribomic.com/eng/pipeline/rbm007.php>